Pelvic exenteration for colorectal and non-colorectal cancer: a comparison of perioperative and oncological outcome.
Pelvic exenteration
Rectal cancer
Recurrence
Surgical complication
Survival
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
accepted:
12
02
2021
pubmed:
8
3
2021
medline:
17
7
2021
entrez:
7
3
2021
Statut:
ppublish
Résumé
Pelvic exenteration (PE) is the only option for long-term cure of advanced cancer originating from different types of tumor or recurrent disease in the lower pelvis. The aim was to show differences between colorectal and non-colorectal cancer in survival and postoperative morbidity. Retrospective data of 63 patients treated with total pelvic exenteration between 2013 and 2018 are reported. Pre-, intra-, and postoperative parameters, survival data, and risk factors for complications were analyzed. A total of 57.2% (n = 37) of the patients had colorectal cancer, 22.3% had gynecological malignancies (vulvar (n = 6) or cervical (n = 8) cancer), 11.1% (n = 7) had anal cancer, and 9.5% had other primary tumors. A total of 30.2% (n = 19) underwent PE for a primary tumor and 69.8% (n = 44) for recurrent cancer. The 30-day in-hospital mortality was 0%. Neoadjuvant treatment was administered to 65.1% (n = 41) of the patients and correlated significantly with postoperative complications (odds ratio 4.441; 95% CI: 1.375-14.342, P > 0.05). R0, R1, R2, and Rx resections were achieved in 65.1%, 19%, 1.6%, and 14.3% of the patients, respectively. In patients undergoing R0 resection, 2-year OS and RFS were 73.2% and 52.4%, respectively. Resection status was a significant risk factor for recurrence-free and overall survival (OS) in univariate analysis. Multivariate analysis revealed age (P = 0.021), ASA ≥ 3 (P = 0.005), high blood loss (P = 0.028), low preoperative hemoglobin level (P < 0.001), nodal positivity (P < 0.001), and surgical complications (P = 0.003) as independent risk factors for OS. Pelvic exenteration is a procedure with high morbidity rates but remains the only curative option for advanced or recurrent colorectal and non-colorectal cancer in the pelvis.
Sections du résumé
BACKGROUND
BACKGROUND
Pelvic exenteration (PE) is the only option for long-term cure of advanced cancer originating from different types of tumor or recurrent disease in the lower pelvis. The aim was to show differences between colorectal and non-colorectal cancer in survival and postoperative morbidity.
METHODS
METHODS
Retrospective data of 63 patients treated with total pelvic exenteration between 2013 and 2018 are reported. Pre-, intra-, and postoperative parameters, survival data, and risk factors for complications were analyzed.
RESULTS
RESULTS
A total of 57.2% (n = 37) of the patients had colorectal cancer, 22.3% had gynecological malignancies (vulvar (n = 6) or cervical (n = 8) cancer), 11.1% (n = 7) had anal cancer, and 9.5% had other primary tumors. A total of 30.2% (n = 19) underwent PE for a primary tumor and 69.8% (n = 44) for recurrent cancer. The 30-day in-hospital mortality was 0%. Neoadjuvant treatment was administered to 65.1% (n = 41) of the patients and correlated significantly with postoperative complications (odds ratio 4.441; 95% CI: 1.375-14.342, P > 0.05). R0, R1, R2, and Rx resections were achieved in 65.1%, 19%, 1.6%, and 14.3% of the patients, respectively. In patients undergoing R0 resection, 2-year OS and RFS were 73.2% and 52.4%, respectively. Resection status was a significant risk factor for recurrence-free and overall survival (OS) in univariate analysis. Multivariate analysis revealed age (P = 0.021), ASA ≥ 3 (P = 0.005), high blood loss (P = 0.028), low preoperative hemoglobin level (P < 0.001), nodal positivity (P < 0.001), and surgical complications (P = 0.003) as independent risk factors for OS.
CONCLUSION
CONCLUSIONS
Pelvic exenteration is a procedure with high morbidity rates but remains the only curative option for advanced or recurrent colorectal and non-colorectal cancer in the pelvis.
Identifiants
pubmed: 33677655
doi: 10.1007/s00384-021-03893-y
pii: 10.1007/s00384-021-03893-y
pmc: PMC8279979
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1701-1710Informations de copyright
© 2021. The Author(s).
Références
Brunschwig A (1948) Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1(2):177–183
doi: 10.1002/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO;2-A
Zaborowski A, Stakelum A, Winter DC (2019) Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer. Br J Surg 106(8):979–987
doi: 10.1002/bjs.11171
de Gregorio N et al (2019) Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet
Zoucas E, Frederiksen S, Lydrup ML, Månsson W, Gustafson P, Alberius P (2010) Pelvic exenteration for advanced and recurrent malignancy. World J Surg 34(9):2177–2184
doi: 10.1007/s00268-010-0637-7
Platt E, Dovell G, Smolarek S (2018) Systematic review of outcomes following pelvic exenteration for the treatment of primary and recurrent locally advanced rectal cancer. Tech Coloproctol 22(11):835–845
doi: 10.1007/s10151-018-1883-1
PelvEx C (2018) Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg 105(6):650–657
doi: 10.1002/bjs.10734
PelvExCollaborative P (2019) exenteration for advanced nonrectal pelvic malignancy. Ann Surg 270(5):899–905
doi: 10.1097/SLA.0000000000003533
Solomon MJ, Brown KGM, Koh CE, Lee P, Austin KKS, Masya L (2015) Lateral pelvic compartment excision during pelvic exenteration. Br J Surg 102(13):1710–1717
doi: 10.1002/bjs.9915
Hahnloser D, Nelson H, Gunderson LL, Hassan I, Haddock MG, O’Connell MJ, Cha S, Sargent DJ, Horgan A (2003) Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg 237(4):502–508
pubmed: 12677146
pmcid: 1514480
Bouchard P, Efron J (2010) Management of recurrent rectal cancer. Ann Surg Oncol 17(5):1343–1356
doi: 10.1245/s10434-009-0861-2
Harris CA, Solomon MJ, Heriot AG, Sagar PM, Tekkis PP, Dixon L, Pascoe R, Dobbs BR, Frampton CM, Harji DP, Kontovounisios C, Austin KK, Koh CE, Lee PJ, Lynch AC, Warrier SK, Frizelle FA (2016) The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg 264(2):323–329
doi: 10.1097/SLA.0000000000001524
Diver EJ, Rauh-Hain JA, Del Carmen MG (2012) Total pelvic exenteration for gynecologic malignancies. Int J Surg Oncol 2012:693535
pubmed: 22720150
pmcid: 3376473
Kehlet H (1997) Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 78(5):606–617
doi: 10.1093/bja/78.5.606
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
doi: 10.1097/01.sla.0000133083.54934.ae
Kulu Y, Mehrabi A, Khajeh E, Klose J, Greenwood J, Hackert T, Büchler MW, Ulrich A (2019) Promising long-term outcomes after pelvic exenteration. Ann Surg Oncol 26(5):1340–1349
doi: 10.1245/s10434-018-07090-0
Yang TX, Morris DL, Chua TC (2013) Pelvic exenteration for rectal cancer: a systematic review. Dis Colon Rectum 56(4):519–531
doi: 10.1097/DCR.0b013e31827a7868
Milne T, Solomon MJ, Lee P, Young JM, Stalley P, Harrison JD (2013) Assessing the impact of a sacral resection on morbidity and survival after extended radical surgery for locally recurrent rectal cancer. Ann Surg 258(6):1007–1013
doi: 10.1097/SLA.0b013e318283a5b6
Bogani G, Signorelli M, Ditto A, Martinelli F, Casarin J, Mosca L, Leone Roberti Maggiore U, Chiappa V, Lorusso D, Raspagliesi F (2018) Factors predictive of 90-day morbidity, readmission, and costs in patients undergoing pelvic exenteration. Int J Gynecol Cancer 28(5):975–982
doi: 10.1097/IGC.0000000000001251
Kaneko K, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Watanabe T (2015) Perioperative allogeneic blood transfusion is associated with surgical site infection after abdominoperineal resection-a space for the implementation of patient blood management strategies. Int Surg 100(5):797–804
doi: 10.9738/INTSURG-D-14-00174.1
Laso-Morales M, Jericó C, Gómez-Ramírez S, Castellví J, Viso L, Roig-Martínez I, Pontes C, Muñoz M (2017) Preoperative management of colorectal cancer-induced iron deficiency anemia in clinical practice: data from a large observational cohort. Transfusion 57(12):3040–3048
doi: 10.1111/trf.14278
Lyell NJ, Kitano M, Smith B, Gleisner AL, Backes FJ, Cheng G, McCarter MD, Abdel-Misih S, Jones EL (2019) The effect of preoperative nutritional status on postoperative complications and overall survival in patients undergoing pelvic exenteration: a multi-disciplinary, multi-institutional cohort study. Am J Surg 218:275–280
doi: 10.1016/j.amjsurg.2019.03.021
Wind J, Polle SW, Fung Kon Jin PHP, Dejong CHC, von Meyenfeldt MF, Ubbink DT, Gouma DJ, Bemelman WA, on behalf of the Laparoscopy and/or Fast Track Multimodal ManagementVersus Standard Care (LAFA) study group and the Enhanced Recovery After Surgery (ERAS) group (2006) Systematic review of enhanced recovery programmes in colonic surgery. Br J Surg 93(7):800–809
doi: 10.1002/bjs.5384
Waters PS, Peacock O, Warrier SK, Wakeman C, Eglinton T, Lynch AC, Frizelle FA, Heriot AG, McCormick J (2019) Evolution of pelvic exenteration surgery-resectional trends and survival outcomes over three decades. Eur J Surg Oncol 45(12):2325–2333
doi: 10.1016/j.ejso.2019.07.015
Laporte GA, Zanini LAG, Zanvettor PH, Oliveira AF, Bernado E, Lissa F, Coelho MJP, Ribeiro R, Araujo RLC, Barrozo AJJ, da Costa AF, de Barros Júnior AP, Lopes A, Santos APM, Azevedo BRB, Sarmento BJQ, Marins CAM, Loureiro CMB, Galhardo CAV, Gatelli CN, Quadros CA, Pinto CV, Uchôa DNAO, Martins DRS, Doria-Filho E, Ribeiro EKMA, Pinto ERF, Dos Santos EAS, Gozi FAM, Nascimento FC, Fernandes FG, Gomes FKL, Nascimento GJS, Cucolicchio GO, Ritt GF, de Oliveira GG, Ayala GP, Guimarães GC, Ianaze GC, Gobetti GA, Medeiros GM, Güth GZ, Neto HFC, Figueiredo HF, Simões JC, Ferrari JC, Furtado JPR, Vieira LJ, Pereira LF, de Almeida LCF, Tayeh MRA, Figueiredo PHM, Pereira RSAV, Macedo RO, Sacramento RMM, Cardoso RM, Zanatto RM, Martinho RAM, Araújo RG, Pinheiro RN, Reis RJ, Goiânia SBS, Costa SRP, Foiato TF, Silva TC, Carneiro VCG, Oliveira VR, Casteleins WA (2020) Guidelines of the Brazilian Society of Oncologic Surgery for pelvic exenteration in the treatment of cervical cancer. J Surg Oncol 121(5):718–729
pubmed: 31777095
PelvEx C (2018) Minimally invasive surgery techniques in pelvic exenteration: a systematic and meta-analysis review. Surg Endosc 32(12):4707–4715
doi: 10.1007/s00464-018-6299-5